A proposed $1.65 billion acquisition threatened to create veterinary monopolies across the United States, leaving pet owners with fewer choices, higher prices, and potentially lower-quality care for their most critically ill animals. The deal, orchestrated by corporate giant JAB Consumer Partners to absorb Ethos Veterinary Health, was so anticompetitive that it triggered a formal complaint from the Federal Trade Commission (FTC), that in turn found the merger would violate federal antitrust law.
The case exposes a systemic trend of corporate consolidation that is quietly reshaping an essential service, transforming local veterinary practices into assets controlled by a handful of powerful holding companies.
How the System Was Rigged
The FTC lays out a clear, factual breakdown of how this single transaction would have systematically eliminated competition in multiple metropolitan areas. The strategy was a direct consequence of a corporate growth model built on acquiring competitors.
- The Proposition: JAB Consumer Partners, which already owned National Veterinary Associates (NVA), proposed to acquire Ethos Veterinary Health for approximately $1.65 billion.
- The Monopoly Creation: In Richmond, Virginia, the deal was set to reduce the number of providers for veterinary medical oncology from two to one, creating an absolute monopoly. For pet owners in the region, this would have meant a single corporate entity would control the market for their pets’ cancer treatment.
- The Competitive Collapse: In Washington, D.C., Denver, and San Francisco, the acquisition would have combined two of a very limited number of “competitively significant providers” for a wide range of critical services, including emergency care, internal medicine, neurology, surgery, and critical care.
- The Inevitable Outcome: The FTC warned that the acquisition would allow the newly merged company to “unilaterally exercise market power”. This would eliminate “head-to-head competition,” leading directly to higher prices and a “degradation in quality” for consumers.
- The Direct Cost to Consumers: The harm would be borne directly by families. The FTC noted that specialty and emergency veterinary insurance is “not widely available,” meaning the price hikes from the merger would be paid as “out-of-pocket costs directly by American consumers”.
- The Settlement: To allow the acquisition to proceed, the companies entered a consent agreement with the FTC. Under the final order, they were forced to divest, or sell off, clinics in Virginia, Colorado, and California to approved competitors. Crucially, the settlement allows the companies to avoid admitting they violated the law.
The Consequences: A Market on Life Support
The FTC’s intervention prevented the worst outcomes of this specific deal, but the case itself serves as a brutal diagnosis-y reminder of a market in distress. The consequences of such unchecked consolidation extend far beyond a single transaction.
The mechanics of the veterinary market rely on competition. The FTC complaint notes that specialists and emergency clinics “monitor procedure prices charged by competing… clinics and lower their prices to attract more referrals”.
By eliminating competitors, the merger would have removed this downward pressure on prices, allowing the new corporate giant to “unilaterally raise prices to consumers”. With few or no alternatives, pet owners facing life-or-death emergencies would be forced to pay whatever the dominant provider charged.
Competition in veterinary medicine is fought on “important non-price dimensions,” such as the quality of medical outcomes, communication with clients, and investment in the latest treatments and equipment. All of that on top of price. When a market consolidates into a monopoly or duopoly, the “incentive to compete” on these critical factors is “significantly reduced,” leading to a degradation of care that harms animals and the families who depend on expert treatment.
The Bottom Line: A Systemic Sickness
The official response was a settlement that surgically removed the most blatant monopolies from the deal while allowing the larger $1.65 billion acquisition to close. JAB/NVA was forced to sell a handful of clinics, but its overall size and market power grew substantially. Homies never even had to admit it broke the law neither.
The true disease of society that we’re facing is the “growing trend towards consolidation” that the FTC itself identified as the backdrop for this case. Our exploitative economic system allowed market concentration to reach a crisis point where a single transaction could wipe out competition in four major cities.
Meaningful accountability came in a less visible, but more systemic, part of the order. For the next decade, JAB/NVA is barred from acquiring any competing specialty or emergency veterinary clinic within a 25-mile radius in five states—California, Colorado, Virginia, Maryland, and D.C.—without prior FTC approval. This provision is a tacit admission by regulators that the company’s growth-by-acquisition model is a systemic threat that must be actively managed.
This story is quite old tbh, here is a press release from 2022. Old but still relevant of a story today: https://www.ftc.gov/legal-library/browse/cases-proceedings/211-0174-jab-consumer-partnersvipwethos-veterinary-health-matter
💡 Explore Corporate Misconduct by Category
Corporations harm people every day — from wage theft to pollution. Learn more by exploring key areas of injustice.
- 💀 Product Safety Violations — When companies risk lives for profit.
- 🌿 Environmental Violations — Pollution, ecological collapse, and unchecked greed.
- 💼 Labor Exploitation — Wage theft, worker abuse, and unsafe conditions.
- 🛡️ Data Breaches & Privacy Abuses — Misuse and mishandling of personal information.
- 💵 Financial Fraud & Corruption — Lies, scams, and executive impunity.
